Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting No phase listed Observational

The APS Phenotyping Study

NCT06521502
Conditions
ARDS, Sepsis, Pneumonia
Interventions
Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan
Other · Procedure · Radiation
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • San Francisco, California + 12 more
Conditions
Lymphoma, Large Cell, Diffuse
Interventions
Zevalin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Conditions
Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
31
States / cities
Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Conditions
Pulmonary Disease, Critical Illness
Interventions
There is no intervention in this observational study
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer, Wound, Non-Healed
Interventions
DETEC® pH
Diagnostic Test
Lead sponsor
Progenitec Inc.
Industry
Eligibility
21 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Lake Success, New York • Arlington, Texas
Completed Phase 1Phase 2 Interventional Results available

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

NCT02016235
Conditions
Dent Disease
Interventions
Phosphorus Supplement, Observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy Adult Participants
Interventions
Not listed
Lead sponsor
Ecotera Health LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
51
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 48 more
Conditions
LCA5
Interventions
AAV8.hLCA5
Biological
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
4 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Conditions
Covid19
Interventions
Observational
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 7 more
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
Interventions
Transoral Surgery, External Beam Radiation Therapy, Cisplatin, Incisional Tumor Biopsy, Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment, MD Anderson Dysphagia Index, University of Washington Quality of Life Questionnaire, Euro-QOL 5 dimension scale questionnaire, Modified barium swallow (MBS) evaluation with aspiration-penetration scale
Procedure · Radiation · Drug + 2 more
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New Brunswick, New Jersey • Newark, New Jersey
Conditions
Tattoo; Pigmentation
Interventions
Vibrancy Assessment
Other
Lead sponsor
Ephemeral Solutions Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milford, Connecticut
Completed No phase listed Observational Accepts healthy volunteers

Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease

NCT01821287
Conditions
Congenital Heart Disease, Nutritional Failure
Interventions
CHD
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 12 Months
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Chronic Kidney Disease
Interventions
DyeVert Plus Contrast Reduction System
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Torrance, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Conditions
Depression, End Stage Renal Disease
Interventions
Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington
Conditions
Phenylketonuria (PKU)
Interventions
Pegvaliase
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
12
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more
Active, not recruiting No phase listed Observational

Longitudinal Bladder Cancer Study for Tumour Recurrence

NCT05080998
Conditions
Urothelial Bladder Cancer
Interventions
CxBladder Monitor/Monitor+
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Charleston, South Carolina + 3 more
Conditions
Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
Interventions
N-Acetylcysteine
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Critical Illness, Wounds and Injury, Disease Attributes, Pathologic Processes
Interventions
Automated Titration (O2matic)
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Winston-Salem, North Carolina • Portland, Oregon + 1 more
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions
aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 60 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
San Antonio, Texas
Not yet recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Conditions
Sleep Apnea, Obstructive
Interventions
Adenotonsillectomy, Observation alone / no intervention
Procedure · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
3 Years to 16 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia